Tel Aviv, Israel / Vancouver, Canada, Sept. 06, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that the company has entered into a Clinical Trial Agreement with Johns…

Source

Previous articlePT439 – Introducing Hyphae Leaks: Not Your Average Psychedelic Podcast
Next articleatai Life Sciences to Participate in Upcoming September Investor Conferences